Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM019
- Development stage
- Preclinical
- Lead developer
- Nanomerics
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
MM019 (also known as AnQlar or GCPQ) is a preclinical-stage, mucoadhesive, amphiphilic chitosan derivative developed by Nanomerics and licensed to Virpax. Formulated as an intranasal spray ("Molecular Mask"), MM019 is designed for the prophylaxis of viral infections, including COVID-19 and influenza. The drug consists of quaternary ammonium palmitoyl glycol chitosan, a positively charged polymer that binds electrostatically to negatively charged viral particles such as SARS-CoV-2 and influenza viruses. This electrostatic binding physically blocks the virus from interacting with host cell receptors, such as angiotensin-converting enzyme 2 (ACE2), thereby preventing viral entry and subsequent replication in the nasal mucosa.
- Brand names
- AnQlar
- Other names
- GCPQMolecular MaskN-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosanquaternary ammonium palmitoyl glycol chitosan
Beyond the preview
Go deeper on MM019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM019.